In vivo efficacy and safety of ALX-0081, compared with clopidogrel and abciximab. Safety (○, dashed lines) and efficacy (●, solid lines) of ALX-0081 (A, n = 8), abciximab (B, n = 3), and clopidogrel (C, n = 4) are shown in function of dose in baboons. Efficacy is measured as the percentage of inhibition of CFRs in the modified Folts model and safety as n-fold increase in bleeding from a well-defined wound, compared with control levels. (D) For ALX-0081–treated animals, ex vivo RIPA measurements (□) correlate with in vivo efficacy (■).